AI Verdict
AAPL has stronger fundamentals based on our AI analysis.
ERNAW vs AAPL Fundamental Comparison
| Metric | ERNAW | AAPL |
|---|---|---|
| Revenue | $582,000.0 | $143.8B |
| Net Income | $-14.1M | $42.1B |
| Net Margin | -2,419.9% | 29.3% |
| ROE | -586.6% | 47.7% |
| ROA | -241.4% | 11.1% |
| Current Ratio | 1.01x | 0.97x |
| Debt/Equity | 0.22x | 1.00x |
| EPS | $-2.24 | $2.84 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ERNAW vs AAPL: Frequently Asked Questions
Is ERNAW or AAPL a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), AAPL has stronger fundamentals. ERNAW is rated STRONG SELL (95% confidence) while AAPL is rated BUY (87% confidence). This is not investment advice.
How does ERNAW compare to AAPL fundamentally?
Ernexa Therapeutics Inc. has ROE of -586.6% vs Apple Inc.'s 47.7%. Net margins are -2,419.9% vs 29.3% respectively.
Which stock pays higher dividends, ERNAW or AAPL?
ERNAW has a dividend yield of N/A or no dividend while AAPL has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ERNAW or AAPL for long term?
For long-term investing, consider that ERNAW has STRONG SELL rating with 95% confidence, while AAPL has BUY rating with 87% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ERNAW vs AAPL?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ERNAW vs AAPL, the AI consensus favors AAPL based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.